MASH / MASLD
How GLP-1 receptor agonists work — receptors, gastric emptying, and the satiety pathway.
Definition
Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — the 2023 consensus renamings of NASH and NAFLD. Characterized by hepatic fat accumulation plus inflammation (MASH) or without (MASLD), driven by insulin resistance + obesity. SYNERGY-NASH (Loomba 2024 NEJM, tirzepatide) and ESSENCE (semaglutide phase 3) showed substantial fibrosis improvement, positioning GLP-1s as the first systemic therapies for MASH outside the FXR agonist resmetirom.
Tirzepatide trial reading list (incl. SYNERGY-NASH) →
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Mechanism
- GLP-1 receptor
- GIP receptor
- Dual agonist
- Gastric emptying
- Food noise
- Triple agonist
- Amylin
- GLP-1 tachyphylaxis
- Non-peptide GLP-1 agonist
- A1C (glycated hemoglobin)
- TBWL (Total Body Weight Loss)
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Looking for more depth?
- Tirzepatide trial reading list (incl. SYNERGY-NASH)
- Browse the full GLP-1 glossary (124 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers